^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    BCL2L1 underexpression

    i
    Other names: BCL2L1, Bcl-X, bcl-xL, bcl-xS, BCL2L, BCLX, PPP1R52, BCL2-like 1
    Entrez ID:
    598
    Related biomarkers:
    Expression
    Mutation
    Others
    12ms
    Evaluation of Neddylation and Apoptosis-Related Gene Expression in Patients with Acute Myeloid Leukemia (ASH 2023)
    Intensive treatment was introduced in 43% of pts, while 25% were treated with azacitidine+venetoclax. Our preliminary results did not prove significant differences in the effect of neddylation gene expression levels on the prognosis of AML patients. As studies are emerging on the potential of neddylation-targeted therapies, we are conducting further research to verify the effect of neddylation on AML.
    Clinical
    |
    FLT3 (Fms-related tyrosine kinase 3) • NPM1 (Nucleophosmin 1) • BCL2L11 (BCL2 Like 11) • CUL4A (Cullin 4A) • BAX (BCL2-associated X protein) • CASP3 (Caspase 3) • CUL1 (Cullin 1) • PMAIP1 (Phorbol-12-Myristate-13-Acetate-Induced Protein 1) • CASP7 (Caspase 7) • CUL7 (Cullin 7) • BAK1 (BCL2 Antagonist/Killer 1) • BBC3 (BCL2 Binding Component 3) • CUL2 (Cullin 2) • NEDD8 (NEDD8 Ubiquitin Like Modifier) • CUL9 (Cullin 9)
    |
    FLT3-ITD mutation • FLT3 mutation • NPM1 mutation • BCL2 expression • BAX expression • BCL2L1 underexpression
    |
    Venclexta (venetoclax) • azacitidine
    almost3years
    An integrative genomics approach identifies MCL-1 as a therapeutic target in childhood high-grade gliomas (LCC 2022)
    Integration of functional dependency with whole transcriptomic data across the adult and paediatric glioma cohorts revealed that MCL-1 dependency was highly correlated with low expression of other BCL-2 family members. Collectively, this study identifies MCL-1 as a new therapeutic target for pHGG patients with low BCL2L1 expression and more broadly highlights the power of integrative genomics to identify biomarker-enabled therapeutic strategies.
    Clinical • IO biomarker
    |
    EGFR (Epidermal growth factor receptor) • PTEN (Phosphatase and tensin homolog) • BCL2 (B-cell CLL/lymphoma 2) • BCL2L1 (BCL2-like 1)
    |
    PTEN mutation • BCL2 expression • BCL2L1 underexpression
    over4years
    Rhabdoid Tumors Are Sensitive to the Protein-Translation Inhibitor Homoharringtonine. (PubMed, Clin Cancer Res)
    RT cell lines and xenografts are highly sensitive to HHT, at least partially due to their low expression of BCL2L1. HHT may have therapeutic potential against RTs.
    Journal
    |
    MCL1 (Myeloid cell leukemia 1) • BCL2L1 (BCL2-like 1)
    |
    BCL2L1 overexpression • BCL2L1 underexpression
    |
    Synribo (omacetaxine mepesuccinate)